As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Arbutus Biopharma Corp. The largest reported stake is Roivant Sciences Ltd.'s, at 19.5%. 11 filings are on record since August 13, 2025 (Schedule 13D/A, October 5, 2026).
Sell to companies like Arbutus Biopharma Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 14,033,488 · Shared voting: 0 · Sole dispositive: 14,331,732 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Morgan Stanley · Sole voting: 0 · Shared voting: 18,663,982 · Sole dispositive: 0 · Shared dispositive: 18,668,111 · SCHEDULE 13G/A, 2026-10-07
- · Reporting person: Roivant Sciences Ltd. · Sole voting: 29,880,079 · Shared voting: 0 · Sole dispositive: 29,880,079 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-10-05
- · Holder: Whitefort Capital Master Fund, LP · Percent: 8% · Shares: 15,794,261 · SCHEDULE 13G
- · Holder: Morgan Stanley · Percent: 8.8% · SCHEDULE 13G/A
Arbutus Biopharma Corp has 11 Schedule 13D or 13G filings on record since 2025-08-13. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 19.5% | 29,880,079 | SCHEDULE 13D/A, 2026-10-05 | 2026-10-01 |
| 12.2% | 18,682,708 | SCHEDULE 13G/A, 2026-10-07 | 2026-09-30 | |
| Two Seas Capital LP | 9.4% | 18,557,543 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Whitefort Capital Master Fund, LP | 8% | 15,794,261 | SCHEDULE 13G, 2026-09-04 | 2026-09-04 |
| BlackRock, Inc. | 7.2% | 14,331,732 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
Holding shares or following this stake? See who's behind Arbutus Biopharma Corp and the warning signs.
Free to see. No signup.
Keep reading
More on Arbutus Biopharma Corp and the records around it.
Arbutus Biopharma Corp elsewhere on the record
Companies that share a holder
- Roivant Sciences Ltd. also filed stake reports on 1 other company: Immunovant, Inc. (Dec 2025)
- Whitefort Capital Master Fund, LP also filed stake reports on 3 other companies: OmniAb, Inc. (Aug 2026), Bally's Corp (Mar 2026), INNOVATE Corp. (Nov 2025)
- Two Seas Capital LP also filed stake reports on 14 other companies: NEKTAR THERAPEUTICS (Sep 2026), Calumet, Inc. (Aug 2026), Quantum Corporation (Aug 2026)
Watch Arbutus Biopharma Corp
Get an email when Arbutus Biopharma Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arbutus Biopharma Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Arbutus Biopharma Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arbutus Biopharma Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | 29,880,079 | 0 | 29,880,079 | 0 | SCHEDULE 13D/A, 2026-10-05 |
| Morgan Stanley | 0 | 18,663,982 | 0 | 18,668,111 | SCHEDULE 13G/A, 2026-10-07 |
| Morgan Stanley Investment Management Inc. | 0 | 17,376,366 | 0 | 17,376,366 | SCHEDULE 13G/A, 2026-10-07 |
| Whitefort Capital Master Fund, LP | 0 | 15,794,261 | 0 | 15,794,261 | SCHEDULE 13G, 2026-09-04 |
| Whitefort Capital GP, LLC | 0 | 15,794,261 | 0 | 15,794,261 | SCHEDULE 13G, 2026-09-04 |
| Whitefort Capital Management, LP | 0 | 15,794,261 | 0 | 15,794,261 | SCHEDULE 13G, 2026-09-04 |
| Whitefort Capital Management GP, LLC | 0 | 15,794,261 | 0 | 15,794,261 | SCHEDULE 13G, 2026-09-04 |
| David Salanic | 0 | 15,794,261 | 0 | 15,794,261 | SCHEDULE 13G, 2026-09-04 |
| Joseph Kaplan | 0 | 15,794,261 | 0 | 15,794,261 | SCHEDULE 13G, 2026-09-04 |
| BlackRock, Inc. | 14,033,488 | 0 | 14,331,732 | 0 | SCHEDULE 13G/A, 2026-10-27 |
The latest filing identifies Arbutus Biopharma Corp by CUSIP 03879J100 and gives its principal executive office as 701 Veterans Circle, Warminster, PA 18974 (SCHEDULE 13G/A, 2026-10-27).
What the percentages are based on
The following percentages are based on 198,105,743 Shares outstanding as of August 19, 2026, which is the total number of Shares outstanding as reported in the Issuer's tender offer statement on Schedule TO filed with the Securities and Exchange Commission on August 24, 2026.Whitefort Capital Master Fund, LP, SCHEDULE 13G, 2026-09-04
Purpose of Transaction (Item 4)
Roivant Sciences Ltd.
Item 4 is hereby amended by adding the following to the end thereof: On August 24, 2026, the Issuer commenced a modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its Common Shares at prices between US$5.00 and US$5.75 per Common Share (the "Offer"), which included the option for shareholders to make a proportionate tender. Roivant made a proportionate tender of its Common Shares in the Offer in order to maintain its proportionate ownership of the Common Shares following completion of the Offer. The Offer expired at 5:00 p.m., New York City time, on September 29, 2026. On October 1, 2026, the Issuer announced that it had taken up and accepted for purchase 46,000,000 Common Shares at a purchase price of US$5.00 per Common Share, including 8,967,383 Common Shares tendered by Roivant pursuant to its proportionate tender, for aggregate consideration to Roivant of approximately US$44,836,915. Following completion of the Offer, Roivant continues to beneficially own approximately 19.5% of the outstanding Common Shares.Item 4 of the SCHEDULE 13D/A filed 2026-10-05
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Two Seas Capital LP | 5.4% | SCHEDULE 13G |
| 2026-02-11 | Morgan Stanley | 13.5% | SCHEDULE 13G/A |
| 2026-02-17 | Two Seas Capital LP | 6.5% | SCHEDULE 13G/A |
| 2026-04-13 | Whitefort Capital Management, LP | 8.1% | SCHEDULE 13D/A |
| 2026-04-28 | Whitefort Capital Management, LP | 8% | SCHEDULE 13D/A |
| 2026-05-15 | Two Seas Capital LP | 9.4% | SCHEDULE 13G/A |
| 2026-08-12 | Morgan Stanley | 8.8% | SCHEDULE 13G/A |
| 2026-09-04 | Whitefort Capital Master Fund, LP | 8% | SCHEDULE 13G |
| 2026-10-05 | Roivant Sciences Ltd. | 19.5% | SCHEDULE 13D/A |
| 2026-10-07 | Morgan Stanley | 12.2% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 7.2% | SCHEDULE 13G/A |
Questions about who owns Arbutus Biopharma Corp
Who owns Arbutus Biopharma Corp?
On this page, 5 holders' latest ownership filings report 5% or more of Arbutus Biopharma Corp: Roivant Sciences Ltd. (19.5%, Schedule 13D/A, filed 2026-10-05), Morgan Stanley (12.2%, Schedule 13G/A, filed 2026-10-07), Two Seas Capital LP (9.4%, Schedule 13G/A, filed 2026-05-15), Whitefort Capital Master Fund, LP (8%, Schedule 13G, filed 2026-09-04) and BlackRock, Inc. (7.2%, Schedule 13G/A, filed 2026-10-27).
Who are the largest shareholders of Arbutus Biopharma Corp?
By the share each holder's latest filing reports, the largest holders of Arbutus Biopharma Corp on this page are Roivant Sciences Ltd. (19.5%), Morgan Stanley (12.2%) and Two Seas Capital LP (9.4%).
When did Roivant Sciences Ltd. buy into Arbutus Biopharma Corp?
The filings give report dates, not purchase dates. The earliest filing from Roivant Sciences Ltd. on this page is the Schedule 13D/A, filed 2026-10-05, reporting 19.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Arbutus Biopharma Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.